Phathom Pharmaceuticals (NASDAQ:PHAT - Get Free Report) is projected to release its earnings data before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($1.29) per share and revenue of $25.65 million for the quarter. Investors that are interested in participating in the company's conference call can do so using this link.
Shares of NASDAQ:PHAT opened at $5.79 on Thursday. Phathom Pharmaceuticals has a 12-month low of $5.21 and a 12-month high of $19.71. The company has a market cap of $395.90 million, a PE ratio of -1.02 and a beta of 0.54. The stock has a 50 day moving average of $6.65 and a 200 day moving average of $11.57.
In related news, COO Azmi Nabulsi sold 7,886 shares of the stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $6.59, for a total value of $51,968.74. Following the transaction, the chief operating officer now owns 233,390 shares of the company's stock, valued at $1,538,040.10. This represents a 3.27 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Terrie Curran sold 19,109 shares of the firm's stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $6.59, for a total value of $125,928.31. Following the transaction, the insider now owns 360,465 shares in the company, valued at approximately $2,375,464.35. This represents a 5.03 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 35,987 shares of company stock worth $240,551 over the last quarter. Company insiders own 24.10% of the company's stock.
A number of research analysts recently weighed in on PHAT shares. Needham & Company LLC restated a "buy" rating and set a $28.00 target price on shares of Phathom Pharmaceuticals in a research note on Friday, January 10th. Cantor Fitzgerald raised shares of Phathom Pharmaceuticals to a "strong-buy" rating in a report on Tuesday. Finally, HC Wainwright reissued a "buy" rating and set a $28.00 price objective on shares of Phathom Pharmaceuticals in a research note on Thursday, December 12th. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Phathom Pharmaceuticals currently has an average rating of "Buy" and an average price target of $23.00.
Read Our Latest Research Report on Phathom Pharmaceuticals
Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Phathom Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phathom Pharmaceuticals wasn't on the list.
While Phathom Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.